Evidence map›Paper›PMID 27337475›Full record

ReviewMicrobiology spectrum2016

Clostridium difficile Infection.

Jae Hyun Shin, Esteban Chaves-Olarte, Cirle A Warren

Abstract readReview
In one paragraph

Review in Microbiology spectrum, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Trial
  2. Article
  3. Open forum infectious diseases · 2026
    Article
  4. Article
  5. Article
  6. Lipidomics, Microbiota, and IntestinalInternational journal of molecular sciences · 2025
    Review
  7. Article
  8. Journal of medical microbiology · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Imaging Inflammation and Infection in the Gastrointestinal Tract.International journal of molecular sciences · 2019
    Review
  13. Vegetative Cell and Spore Proteomes ofJournal of proteome research · 2019
    Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jae Hyun ShinDepartment of Medicine, Division of Infectious Disease and International Health, University of Virginia, Charlottesville, VA 22908.
Esteban Chaves-OlarteCentro de Investigación en Enfermedades Tropicales, Facultad de Microbiología, Universidad de Costa Rica, Costa Rica.
Cirle A WarrenDepartment of Medicine, Division of Infectious Disease and International Health, University of Virginia, Charlottesville, VA 22908.

Funding

INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
NIAID NIH HHS T32 AI007046
6 · The paper itself

Abstract

Clostridium difficile is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus that has long been recognized to be the most common etiologic pathogen of antibiotic-associated diarrhea. C. difficile infection (CDI) is now the most common cause of health care-associated infections in the United States and accounts for 12% of these infections (Magill SS et al., N Engl J Med370:1198-1208, 2014). Among emerging pathogens of public health importance in the United States, CDI has the highest population-based incidence, estimated at 147 per 100,000 (Lessa FC et al., N Engl J Med372:825-834, 2015). In a report on antimicrobial resistance, C. difficile has been categorized by the Centers for Disease Control and Prevention as one of three "urgent" threats (http://www.cdc.gov/drugresistance/threat-report-2013/). Although C. difficile was first described in the late 1970s, the past decade has seen the emergence of hypertoxigenic strains that have caused increased morbidity and mortality worldwide. Pathogenic strains, host susceptibility, and other regional factors vary and may influence the clinical manifestation and approach to intervention. In this article, we describe the global epidemiology of CDI featuring the different strains in circulation outside of North America and Europe where strain NAP1/027/BI/III had originally gained prominence. The elderly population in health care settings has been disproportionately affected, but emergence of CDI in children and healthy young adults in community settings has, likewise, been reported. New approaches in management, including fecal microbiota transplantation, are discussed.

Indexed as

Enterocolitis, PseudomembranousAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsClostridioides difficileCross InfectionEnterotoxinsHumansProbioticsAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsEnterotoxinstcdA protein, Clostridium difficiletoxB protein, Clostridium difficile

Identifiers

PMID27337475
PMCPMC8118380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.